Moreover, prior researches has demonstrated the predictive value of plasma VAP-1 for adverse cardiovascular events in several different diseases and populations, including patients with coronary artery disease, type 2 diabetes mellitus, those undergoing hemodialysis, and individuals aged ≥50 years without a prior history of major adverse cardiovascular events (MACE) (8, 20–22). This evidence concerns the gene AOC3 and diabetes mellitus.